Zyprexa At "Halftime": Lilly Remains Committed To Antipsychotic

Lilly's 2005 marketing strategy aims to stem declining sales for the atypical antipsychotic Zyprexa, Exec. VP-Pharmaceutical Operation John Lechleiter, PhD, said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet